{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":44,"n_cols":5,"rows_kept":44,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[12,2,12,3],[14,2,14,3],[15,2,15,3],[19,2,19,3],[27,2,27,3],[27,4,27,5],[28,2,28,3],[28,4,28,5],[29,2,29,3],[30,2,30,3],[32,2,32,3],[33,2,33,3],[34,2,34,3],[35,2,35,3],[39,2,39,3],[40,2,40,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910782612503321"]
[null,null,"Autore",null,"Airley Rachel"]
[null,null,"Titolo",null,"Cancer chemotherapy [[electronic resource] /] / Rachel Airley"]
[null,null,"Pubbl/distr/stampa",null,"Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009"]
[null,null,"ISBN",null,"1-282-11217-1"]
[{"$nulls":4},"9786612112171"]
[{"$nulls":4},"0-470-09254-8"]
[{"$nulls":4},"0-470-09256-4"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (362 p.)"]
[null,null,"Disciplina",null,"616.99/4061"]
[{"$nulls":4},"616.994061"]
[null,null,"Soggetti",null,"Cancer - Chemotherapy"]
[{"$nulls":4},"Chemotherapy"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Cancer Chemotherapy; Contents; Preface; 1 Cancer epidemiology; 1.1 Cancer incidence, prevalence and mortality; 1.2 Childhood cancers; 1.3 Global epidemiology; 2 Histopathology of cancer; 2.1 Introduction; 2.2 Malignant, benign and normal (non-malignant) tissue; 2.3 Cell death; 3 Carcinogenesis, malignant transformation and progression; 3.1 Introduction; 3.2 Chemical carcinogenesis; 4 Molecular biology of cancer: oncogenes and tumour suppressor genes; 4.1 Introduction; 4.2 Oncogenesis; 4.3 Tumour suppressor genes; 5 Tumour metastasis: a convergence of many theories; 5.1 Introduction"]
[{"$nulls":4},"5.2 Detachment and migration from the primary tumour5.3 Intravasation; 5.4 Transport; 5.5 Extravasation; 5.6 Growth of the metastatic tumour mass; 6 Health professionals in the treatment of cancer; 6.1 Introduction; 6.2 Pathology; 6.3 Radiology; 6.4 Role of the surgical oncologist; 6.5 Oncology pharmacy; 6.6 Oncology nursing; 6.7 The NHS Cancer Plan; 7 Principles of cancer chemotherapy; 7.1 Introduction; 7.2 Timing of chemotherapy; 7.3 Biomarkers and their uses; 7.4 Clinical assessment of biomarkers; 7.5 Pharmacogenetics and pharmacogenomics of cancer chemotherapy"]
[{"$nulls":4},"8 Classical anticancer agents8.1 Introduction; 8.2 Alkylating agents; 8.3 Antimetabolites; 8.4 Agents derived from natural or semisynthetic products; 8.5 Hormonal anticancer agents; 8.6 Clinically used chemotherapy regimens; 9 The philosophy of cancer research; 9.1 "]
[{"$nulls":4},"Introduction; 9.2 Structure of cancer research organizations in the United Kingdom; 9.3 Cancer research in the United States; 10 Novel anticancer agents; 10.1 Introduction; 10.2 Target validation; 10.3 Identification and optimization of lead drugs; 10.4 Preclinical pharmacology; 11 Clinical trials; 11.1 Introduction"]
[{"$nulls":4},"11.2 Evaluation of treatment response11.3 Assessment of vascularity and angiogenesis by nuclear medicine technology; 12 Tumour hypoxia; 12.1 Introduction; 12.2 Bioreductive drugs; 12.3 Inhibitors of HIF-1 and HIF-1-regulated genes; 13 Antiangiogenic and antivascular agents; 13.1 History of angiogenesis as a therapeutic target; 13.2 Anti-angiogenic drug targets; 13.3 The return of thalidomide; 13.4 Monoclonal antibodies as anti-angiogenic agents; 13.5 The hollow fibre assay as a drug screen for anti-angiogenic drugs; 13.6 Vascular disrupting agents; 14 Tyrosine kinase inhibitors"]
[{"$nulls":4},"14.1 Introduction14.2 Tyrosine kinase inhibitors targeting angiogenesis; 14.3 Non-receptor tyrosine kinase inhibitors; 15 Ras inhibitors; 16 Inhibitors of the Akt/PKB pathway; 17 Targeting stress proteins: HSP90 inhibitors; 18 The proteasome; 18.1 Introduction; 18.2 The proteasome as a target for novel drug strategies; 18.3 Ubiquitylation as a target; 19 Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR); 19.1 Mammalian target of rapamycin; 19.2 Structure and activation of mTOR; 19.3 Novel anticancer agents targeting mTOR; 20 Telomerase"]
[{"$nulls":4},"21 Histone deacetylase: an epigenetic drug target"]
[null,null,null,"Sommario/riassunto","This textbook is a clear and accessible introduction to the scientific and clinical aspects of the creation, development and administration of drugs or drug regimens used in the treatment of cancer. Unique in its approach, this book enables the student to gain an understanding of the pathological, physiological and molecular processes governing malignancy, whilst also introducing the role of health professionals and scientists in the research and treatment of cancer. The book consolidates all the essential information necessary for a full understanding of cancer chemotherapy, providing an info"]
[null,"2.","Record Nr.",null,"UNINA9910966338703321"]
[null,null,"Titolo",null,"Uzbekistan : communications / / World Trade Press"]
[null,null,"Pubbl/distr/stampa",null,"Petaluma, Calif., : World Trade Press, c1993-2010 [2010]"]
[null,null,"ISBN",null,"9781607806271"]
[{"$nulls":4},"1607806274"]
[null,null,"Edizione",null,"[2nd ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (27 p.)"]
[null,null,"Disciplina",null,"302.2309"]
[null,null,"Soggetti",null,"Communication - Uzbekistan"]
[{"$nulls":4},"Communication and traffic - Uzbekistan"]
[{"$nulls":4},"Telecommunication - Uzbekistan"]
[{"$nulls":4},"Mobile communication systems - Uzbekistan"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Cover title."]
[null,null,null,"Sommario/riassunto","Get all three comprehensive reports bundled into one for a complete media and communications profile of Uzbekistan. An excellent source of practical information, this profile offers an extensive dialing guide with city codes, a listing of ISPs and Internet cafes, profiles of the major media outlets (with contact info!) and more."]